PHENOCNU IN AD & ALS TREATMENT
PIPELINE
Further Pipeline to PHENOGENE-1A: PHENOCNU-10 and PHENOCNU-12 Candidates in Development
Beyond the primary programs, PHENOCNU-10 and PHENOCNU-12 are in early preclinical testing. Initial findings suggest they may limit amyloid-β and tau aggregation, while also dampening mitogen-activated protein (MAP) kinase and nuclear factor kappa B (NF-κB) activity—early drivers of inflammation.
In exploratory models, both compounds inhibited LPS-induced COX-2 and iNOS expression, markers of late-stage neuroinflammation.
Together, these data point to PHENOCNU-10 and PHENOCNU-12 as complementary candidates for neuroprotection and inflammation control in Alzheimer Disease, ALS, and related disorders.
Pipeline:
PHENOGENE-1A
& CNU Development
Milestones Use of Proceeds and Existing Cash Through 2028 ($70-100M Raise)
